Hikma Opens Discussions To Acquire GSK Businesses In Egypt And Tunisia
Deal Would Include Hikma Acquiring GSK’s 91.2% Holding
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
You may also be interested in...
Hikma and GSK have agreed not to proceed with a deal being explored by the two firms that would have seen Hikma acquire a majority stake in the firm’s pharmaceutical and consumer health business in Egypt and Tunisia.
Hikma CEO Siggi Olafsson has outlined the potential future opportunity that the firm sees in the US biosimilars market, in the second part of an exclusive interview with Generics Bulletin.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.